Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mind the Gaps: Dolutegravir PK in Pediatric HIV/TB Cotreatment
NCT05069688Phase 1Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifampicin and dolutegravir in human immunodeficiency virus infection (HIV) and Tuberculosis (TB), sponsored by Brigham and Women's Hospital. Primary endpoint: Dolutegravir Area Under the Curve at 22 weeks. Started Jul 2023; status: recruiting.
02
Drugs
rifampicindolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05069688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069688.